JPRN-UMIN000050137招募中Unknown
One-year outcomes of switching to brolucizumab in nAMD refractory to aflibercept - Efficacy of switching to brolucizumab for wet age-related macular degeneration
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 50years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with CNV as a result of high myopia, angioid streaks, hereditary disorders, or uveitis were excluded.
研究者
相似试验
已完成
3 期
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic RetinopathyProliferative Diabetic RetinopathyNCT04278417Novartis Pharmaceuticals689
进行中（未招募）
1 期
Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab.EUCTR2019-004099-20-GREO Pharma A/S120
进行中（未招募）
1 期
Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab.adult subjects with moderate-to-severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2019-004099-20-GBEO Pharma A/S260
进行中（未招募）
1 期
Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab.adult subjects with moderate-to-severe plaque psoriasisMedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2019-004099-20-NLEO Pharma A/S260
进行中（未招募）
1 期
Efficacy and safety of brodalumab compared with guselkumab in the treatment of plaque psoriasis after inadequate response to ustekinumab.EUCTR2019-004099-20-ATEO Pharma A/S240